Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC

PHASE3TerminatedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Non-small-cell Lung Cancer
Interventions
DRUG

Docetaxel

Docetaxel at the dose of 30mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles

DRUG

Gemcitabine

Gemcitabine at the dose of 900mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles

DRUG

Gemcitabine

Gemcitabine at the dose of 1200mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles

Trial Locations (9)

Unknown

University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli

"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens

401 Military Hospital, Medical Oncology Unit, Athens

Air Forces Military Hospital, Dep of Medical Oncology, Athens

"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens

Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases, Athens

"Sotiria General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases", Athens

"Metaxa's Anticancer Hospital of Piraeus,1st Dep of Medical Oncology", Piraeus

"Theagenion Anticancer Hospital of Thessaloniki", Thessaloniki

All Listed Sponsors
collaborator

University Hospital of Crete

OTHER

lead

Hellenic Oncology Research Group

OTHER